Compare MPT & STVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MPT | STVN |
|---|---|---|
| Founded | 2003 | 1949 |
| Country | United States | Italy |
| Employees | 121 | N/A |
| Industry | Real Estate Investment Trusts | Containers/Packaging |
| Sector | Real Estate | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.7B |
| IPO Year | N/A | 2021 |
| Metric | MPT | STVN |
|---|---|---|
| Price | $5.20 | $18.11 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 3 |
| Target Price | $5.00 | ★ $25.67 |
| AVG Volume (30 Days) | ★ 4.8M | 588.9K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 6.43% | 0.39% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $9.67 |
| Revenue Next Year | $4.91 | $9.99 |
| P/E Ratio | ★ N/A | $27.15 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.51 | $12.89 |
| 52 Week High | $6.47 | $28.00 |
| Indicator | MPT | STVN |
|---|---|---|
| Relative Strength Index (RSI) | 55.59 | 68.18 |
| Support Level | $4.86 | $13.58 |
| Resistance Level | $6.47 | $26.94 |
| Average True Range (ATR) | 0.17 | 0.89 |
| MACD | 0.01 | 0.24 |
| Stochastic Oscillator | 65.84 | 78.14 |
Medical Properties Trust Inc acquires and develops net-leased healthcare facilities. Its investments in healthcare real estate, other loans, and any investments in tenants are considered a single reportable segment. Its business strategy is to acquire and develop healthcare facilities and lease the facilities to healthcare operating companies under long-term net leases, which require the tenant to bear of the costs associated with the property. The group's geographic areas are the United States, the United Kingdom, and All other countries.
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, It derives its majority revenue from Europe, Middle East and Africa.